The Carnitine PromiseWhat is Carnitine and DoxorubicinThe Story Behind the PromiseThe Clinical Study and Your PhysicianCarnitine's Broad Health Benefits
The Carnitine Promise in Greater DetailLinks to Other ResourcesAbout Dr. Stephen L. Defelice, M.D.


Stephen L. DeFelice, M.D. is sponsoring a study to evaluate the effectiveness of carnitine used in conjunction with pegylated doxorubicin (Doxil) in the treatment of advanced stage ovarian cancer patients. The basis of the study is to determine whether the combination can reduce tumor size over a period of six months. Toxicity will also be monitored. If tumor size remains the same or is reduced, then the patient will continue to receive the therapy for as long as the beneficial effect continues. Intravenous Carnitine therapy will be given along with pegylated doxorubicin approximately every 4 weeks. Oral carnitine will be taken daily.

A call for patient volunteers
Patient recruitment is now in progress. The study will be conducted at a northern New Jersey hospital which is about an hour by car from Manhattan. Patients will not be hospitalized. Karthik Koduru, M.D., will pre-screen patient volunteers and conduct the clinical study.

If you are or someone whom you know would be interested in participating in the study, the procedure is to contact your physician and tell him or her about the study. Your physician should contact Dr. Koduru for more specific information about the details of the study.

e-mail: Karthik_koduru@yahoo.com

Phone: (201) 850-7103

Mail:
Stephen L. DeFelice, M.D.
Box 1220
Mountainside, N.J. 07092

Who may qualify
Patient recruitment is now in progress for applicants in the late stages III through IV of their disease who have become resistant to both platinum and taxane therapy, and where new therapies are desperately needed. Patients who have been or are being treated with an anthracycline drug such as Doxil or Adriamycin are not eligible to participate in the study. If there is anticancer activity shown in this more advanced-stage group then one can expect that treatment would be also effective in earlier stages of ovarian cancer. It is hoped that some idea of the effectiveness of the combination will be known by early 2011.

The drugs
Both drugs are FDA approved and are available to doctors to treat patients for a number of diseases. The good news is that carnitine is extremely safe.

Next page: Carnitine's Broad Health Benefits